| Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ... JAMA neurology 78 (12), 1471-1483, 2021 | 351 | 2021 |
| Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease M Milà-Alomà, NJ Ashton, M Shekari, G Salvadó, P Ortiz-Romero, ... Nature Medicine 28 (9), 1797-1801, 2022 | 322 | 2022 |
| Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ … M Suárez‐Calvet, TK Karikari, NJ Ashton, J Lantero Rodriguez, ... EMBO molecular medicine 12 (12), e12921, 2020 | 316 | 2020 |
| Quantification of amyloid PET for future clinical use: a state-of-the-art review HG Pemberton, LE Collij, F Heeman, A Bollack, M Shekari, G Salvadó, ... European journal of nuclear medicine and molecular imaging 49 (10), 3508-3528, 2022 | 113 | 2022 |
| CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: a cross-sectional study M Mila-Aloma, A Brinkmalm, NJ Ashton, H Kvartsberg, M Shekari, ... Neurology 97 (21), e2065-e2078, 2021 | 65 | 2021 |
| Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent LE Collij, G Salvadó, M Shekari, I Lopes Alves, J Reimand, AM Wink, ... European journal of nuclear medicine and molecular imaging 48, 2169-2182, 2021 | 45 | 2021 |
| P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease J Lantero‐Rodriguez, A Snellman, AL Benedet, M Milà‐Alomà, ... EMBO Molecular Medicine 13 (12), e15098, 2021 | 42 | 2021 |
| Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum N Vilor-Tejedor, I Ciampa, G Operto, C Falcón, M Suárez-Calvet, ... Alzheimer's Research & Therapy 13, 1-13, 2021 | 42 | 2021 |
| Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer’s and Families (ALFA) study, and BioCogBank Paris Lariboisière cohort. Differences between plasma and … AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ... JAMA Neurol 78 (12), 1471-1483, 2021 | 36 | 2021 |
| Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression W Pelkmans, M Shekari, A Brugulat‐Serrat, G Sánchez‐Benavides, ... Alzheimer's & Dementia 20 (1), 483-493, 2024 | 32 | 2024 |
| Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer’s Disease and neurodegeneration … I Cumplido-Mayoral, M García-Prat, G Operto, C Falcon, M Shekari, ... Elife 12, e81067, 2023 | 32 | 2023 |
| A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images M Bucci, I Savitcheva, G Farrar, G Salvadó, L Collij, V Doré, JD Gispert, ... European journal of nuclear medicine and molecular imaging 48, 2183-2199, 2021 | 29 | 2021 |
| Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum G Salvadó, M Milà-Alomà, M Shekari, NJ Ashton, G Operto, C Falcon, ... European journal of nuclear medicine and molecular imaging 49 (13), 4567-4579, 2022 | 27 | 2022 |
| Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers G Salvadó, M Shekari, C Falcon, G Operto, M Milà-Alomà, ... Brain Communications 4 (3), fcac134, 2022 | 26 | 2022 |
| Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum G Salvadó, M Milà‐Alomà, M Shekari, C Minguillon, K Fauria, ... Alzheimer's & Dementia 17 (5), 788-800, 2021 | 24 | 2021 |
| Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are … M Suarez-Calvet, TK Karikari, NJ Ashton, J Lantero Rodríguez, ... DOI: https://doi. org/10.15252/emmm 202012921, 0 | 24 | |
| Analysis of psychological symptoms following disclosure of amyloid–positron emission tomography imaging results to adults with subjective cognitive decline C Caprioglio, F Ribaldi, LNC Visser, C Minguillon, LE Collij, ... JAMA network open 6 (1), e2250921-e2250921, 2023 | 20 | 2023 |
| Regional associations of white matter hyperintensities and early cortical amyloid pathology L Lorenzini, LT Ansems, I Lopes Alves, S Ingala, D Vállez García, ... Brain communications 4 (3), fcac150, 2022 | 19 | 2022 |
| Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial D Altomare, F Barkhof, C Caprioglio, LE Collij, P Scheltens, IL Alves, ... JAMA neurology 80 (6), 548-557, 2023 | 18 | 2023 |
| Comparative analysis of different definitions of amyloid-β positivity to detect early downstream pathophysiological alterations in preclinical Alzheimer M Milà-Alomà, G Salvadó, M Shekari, O Grau-Rivera, A Sala-Vila, ... The Journal of Prevention of Alzheimer's Disease 8, 68-77, 2021 | 18 | 2021 |
